$BDX (Becton, Dickinson and Company)

$BDX {{ '2016-02-03T13:47:53+0000' | timeago}} • Webcast

Diagnostic products maker $BDX's 1Q16 revenues grew 1.8%, which is in line with the prior guidance of 1-2% growth, reflecting solid underlying growth in Medical and Life Sciences segments. Adjusted EPS was $1.96, helped by solid underlying performance of the segments and earnings were ahead of the company's expectations.

$BDX {{ '2017-07-19T13:58:34+0000' | timeago}} • Announcement

$BDX received 510(k) clearance from the FDA for the BD FACSLyric flow cytometer system, an easy-to-use in vitro diagnostic (IVD) system, for use with BD Multitest assays for immunological assessment of individuals and patients having or suspected of having immune deficiency.

$GS {{ '2017-07-19T11:22:37+0000' | timeago}} • Webcast

$GS advised a number of important transactions that were announced during 2Q17, including $BCR's $24Bil sale to $BDX. $AMZN's $13.7Bil acquisition of $WFM, and $DFT's $7.6Bil merger with $DLR.

$BDX {{ '2017-06-12T07:19:32+0000' | timeago}} • Announcement

$BDX and $BCR received a request for additional information from the Federal Trade Commission in connection with BD's pending acquisition of C.R. Bard. In April 2017, BD agreed to buy Bard in a $24Bil transaction. Both companies expect to get regulatory approvals and close the transaction in the fall of 2017.

$BDX {{ '2017-05-02T10:50:46+0000' | timeago}} • Announcement

$BDX now expects FY17 EPS of $7.73-7.83, which represents growth of about 72-74%. On a currency-neutral basis, $BDX still sees adjusted EPS of $9.70-9.80, which includes an estimated 1.5 points of dilution related to the Respiratory Solutions divestiture. Including negative foreign current impact, $BDX still sees adjusted EPS of $9.35-9.45.

$BDX {{ '2017-05-02T10:47:45+0000' | timeago}} • Announcement

$BDX still expects FY17 revenue to decrease 3.5-4%, primarily due to the divestiture of the Respiratory Solutions business. The company continues to estimate that revenues for FY17 to increase 4.5-5.0% on a comparable, currency-neutral basis that excludes Respiratory Solutions and other divestitures that closed in FY16.

$BDX {{ '2017-05-02T10:46:32+0000' | timeago}} • Announcement

As a result of transformation in the U.S. dispensing business within Medication Management Solutions, $BDX's accounting for revenue recognition will change to reflect the new dispensing business model. $BDX sees an unfavorable impact to FY17 of about $50-60MM to revenues and about $0.20-0.25 to adjusted EPS.

$BDX {{ '2017-05-02T10:46:03+0000' | timeago}} • Announcement

$BDX reported a 1.6% rise in 2Q17 earnings driven by lower income tax provision. Net income rose to $344MM or $1.58 per share from $338MM or $1.56 per share last year. Revenue fell to $2.97Bil from $3.07Bil, due to the divestiture of the Respiratory Solutions business. Adjusted EPS increased to $2.30 from $2.18.

$BDX {{ '2017-04-24T15:32:49+0000' | timeago}} • Announcement

$BDX appointed Tom Polen as president of $BDX, effective immediately. In his new role, Mr. Polen will oversee all of BD's operating segments, the Medical and Life Sciences segments, as well as the new Interventional segment, which will include the $BCR businesses following the close of $BDX's acquisition of $BCR.

$BDX {{ '2017-04-24T15:02:53+0000' | timeago}} • Announcement

$BDX appointed Tom Polen as president of $BDX, effective immediately. In his new role, Polen will oversee $BDX's Medical and Life Sciences segments, as well as the new Interventional segment.

$BDX {{ '2017-04-24T15:00:46+0000' | timeago}} • Announcement

$BDX agreed to buy $BCR. About $300MM of annual, pre-tax, run-rate cost synergies are expected by FY20. $BDX also expects to benefit from revenue synergies beginning in FY19. This is expected to improve $BDX's gross margins by about 300 basis points in FY18, increase $BDX's EPS growth trajectory to the mid-teens, and generate strong cash flow.

$BDX {{ '2017-04-24T14:58:54+0000' | timeago}} • Announcement

$BDX agreed to buy $BCR$BCR common shareholders will be entitled to receive about $222.93 in cash and 0.5077 shares of $BDX stock per $BCR share, or a total of value of $317.00 per $BCR common share. This will be immediately accretive and is expected to generate high-single digit accretion to adjusted EPS in FY19.

$BDX {{ '2017-04-24T14:57:11+0000' | timeago}} • Announcement

$BDX agreed to buy $BCR for $317 per share in cash and stock, for a total consideration of $24Bil. The agreement has been unanimously approved by BoDs of both companies. The transaction is expected to close in the fall of 2017. At closing, $BCR shareholders will own about 15% of the combined company.

$BDX {{ '2017-04-05T14:28:15+0000' | timeago}} • Announcement

$BDX acquired Caesarea Medical Electronics (CME), an Israeli-based infusion pump systems manufacturer. In 2014, CareFusion Corp., which was acquired by $BDX in 2015, had acquired a non-controlling 40% stake in CME. This deal completes the acquisition of the remaining 60% of CME. Additional terms of the transaction were not disclosed.

$BDX {{ '2017-02-13T13:16:37+0000' | timeago}} • Announcement

$BDX announced an early access program for the BD Resolve Single-Cell Gene Expression platform that has the flexibility to capture and analyze hundreds to tens of thousands of individual cells in a broad range of sizes and types.

$BDX {{ '2017-02-02T20:26:44+0000' | timeago}} • Webcast

Exiting FY18, $BDX expects to generate $325-350MM in total cost synergies related to the CareFusion acquisition. $BDX added that its manufacturing related synergies remain on track and it expects a majority of these to be achieved in the latter part of deal horizon.

$BDX {{ '2017-02-02T20:16:31+0000' | timeago}} • Webcast

In 1Q17, $BDX recorded a reversal of certain reserves related to a court decision, which among other things, reverse an unfavorable antitrust judgment in the RTI case. Geographically, revenue grew 5.5% in U.S. and 6.8% in International. Developed markets revenue grew 5.8% and emerging markets revenue grew 7.7%.

$BDX {{ '2017-02-02T11:33:40+0000' | timeago}} • Announcement

$BDX now expects FY17 EPS of $7.90-8.00, which represents growth of about 76-78%. On a currency-neutral basis, $BDX lifted FY17 adjusted EPS to $9.70-9.80 from $9.62-9.72. Including incrementally estimated impact from foreign currency, $BDX now sees adjusted EPS of $9.35-9.45, which represents growth of about 9-10% over last year.

$BDX {{ '2017-02-02T11:31:01+0000' | timeago}} • Announcement

$BDX now expects FY17 revenue to decrease 3.5-4%, primarily due to divestiture of the Respiratory Solutions business. This is a reduction in prior forecast of down 3-3.5%, due to the incrementally negative estimated impact from foreign currency. $BDX still expects revenue to increase 4.5-5% on a comparable, currency-neutral basis.

$BDX {{ '2017-02-02T11:29:04+0000' | timeago}} • Announcement

$BDX's worldwide revenue in the BD Life Sciences segment for 1Q17 increased 2.7% from last year or 3.2% on a currency-neutral basis. The segment's revenue growth reflects strong performance in the Diagnostic Systems and Preanalytical Systems units.

$BDX {{ '2017-02-02T11:27:27+0000' | timeago}} • Announcement

$BDX's worldwide revenue in the BD Medical segment for 1Q17 fell 4.4% from last year, due to the divestiture of the Respiratory Solutions business that was completed in October 2016. On a comparable, currency-neutral basis, revenues increased 7.5%. The results reflect strong performance across the segment.

Recent Transcripts

ISRG (Intuitive Surgical, Inc.)
Thursday, July 20 2017 - 8:30pm
MCK (McKesson Corporation)
Thursday, May 18 2017 - 9:00pm
VRML (Vermillion, Inc.)
Thursday, May 11 2017 - 12:30pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
NKTR (Nektar Therapeutics)
Tuesday, May 9 2017 - 9:00pm
XRAY (DENTSPLY International Inc.)
Tuesday, May 9 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, May 9 2017 - 12:00pm
HAE (Haemonetics Corporation)
Monday, May 8 2017 - 12:00pm
SYN (Synthetic Biologics Inc.)
Thursday, May 4 2017 - 8:30pm
BDX (Becton, Dickinson and Company)
Thursday, May 4 2017 - 12:00pm
TFX (Teleflex Incorporated)
Thursday, May 4 2017 - 12:00pm
GMED (Globus Medical, Inc.)
Wednesday, May 3 2017 - 9:30pm
BDX (Becton, Dickinson and Company)
Tuesday, May 2 2017 - 12:00pm
IDXX (IDEXX Laboratories, Inc.)
Friday, April 28 2017 - 12:30pm
HRC (Hill-Rom Holdings, Inc.)
Friday, April 28 2017 - 12:30pm
SNE (Sony Corporation)
Friday, April 28 2017 - 8:15am
VRTX (Vertex Pharmaceuticals Incorporated)
Thursday, April 27 2017 - 8:30pm
RMD (ResMed Inc.)
Thursday, April 27 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, April 27 2017 - 2:30pm
CRY (CryoLife Inc.)
Thursday, April 27 2017 - 12:00pm

AlphaGraphics you may like